Trial Profile
Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies (IMMEDIATE): a pilot study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Dermatomyositis; Muscular disorders; Myositis; Polymyositis
- Focus Therapeutic Use
- Acronyms IMMEDIATE
- Sponsors CSL Behring
- 25 Oct 2020 Status changed from recruiting to completed as per results published in the Rheumatology.
- 25 Oct 2020 Results published in the Rheumatology
- 02 Jul 2019 According to an abstract presented at the 5th Congress of the European Academy of Neurology, 20 patients have been included in this study:dermatomyositis (n=9), non-specific myositis/overlap myositis (n=5), immune-mediated necrotizing myopathy (n=5), and anti-synthetase syndrome (n=1). Primary and secondary endpoints results will be presented at the conference.